Home›Ivosidenib›Ivosidenib + Sensitive Cyp3a Substrates

Does Ivosidenib Interact with Sensitive Cyp3a Substrates?

Ivosidenib and Sensitive Cyp3a Substrates have a contraindicated drug interaction according to U.S. FDA drug labeling data. Ivosidenib induces CYP3A4, decreasing concentrations of sensitive substrates and risking loss of therapeutic effect. Avoid concomitant use. The mechanism involves ivosidenib induces cyp3a4, decreasing substrate concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Ivosidenib Class
Isocitrate Dehydrogenase 1 Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Ivosidenib and Sensitive Cyp3a Substrates occurs because ivosidenib induces cyp3a4, decreasing substrate concentrations. Clinically, this means ivosidenib induces cyp3a4, decreasing concentrations of sensitive substrates and risking loss of therapeutic effect. avoid concomitant use. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Ivosidenib and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Ivosidenib+💊 Sensitive Cyp3a Substrates

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Isocitrate Dehydrogenase 1 Inhibitor
Drug B class
—
Source
NLP:ivosidenib

What this means in plain English

Ivosidenib induces CYP3A4, decreasing concentrations of sensitive substrates and risking loss of therapeutic effect. Avoid concomitant use.

What the FDA label says

"Ivosidenib induces CYP3A4, decreasing substrate concentrations"

📖 Source: NLP:ivosidenib

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Ivosidenib and Sensitive Cyp3a Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.